Latest News on ERAS

Financial News Based On Company


Advertisement
Advertisement

Erasca and Bristol Myers Squibb partner to test ERAS-0015 with navlimetostat in pancreatic cancer trial

https://pluang.com/en/news-feed/kerjasama-klinis-erasca-bristol-myers-squibb-uji-obat-pan-ras
Erasca, Inc. has announced a clinical collaboration with Bristol Myers Squibb to investigate the combination of Erasca's pan-RAS molecular glue, ERAS-0015, and BMS's investigational PRMT5 inhibitor, navlimetostat. This Phase 1/2 trial will focus on treating MTAP-deleted pancreatic ductal adenocarcinoma, with BMS sponsoring the study and Erasca providing ERAS-0015. The partnership aims to enhance treatment efficacy for pancreatic cancer patients with RAS mutations by leveraging the complementary mechanisms of both drugs.

Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with Navlimetostat

https://www.quantisnow.com/insight/erasca-enters-into-clinical-collaboration-with-bristol-myers-squibb-to-6797542
Erasca and Bristol Myers Squibb have formed a clinical collaboration to evaluate Erasca's ERAS-0015 in combination with BMS's navlimetostat for patients with MTAP-deleted pancreatic ductal adenocarcinoma. Bristol Myers Squibb will sponsor the Phase 1/2 trial, with Erasca supplying ERAS-0015, while both companies retain their development and commercial rights. The agreement does not include upfront payments, milestones, or royalties, making the financial value for Erasca currently unknown.

Form 144 Erasca Inc. For: 16 November By Investing.com

https://in.investing.com/news/stock-market-news/form-144-erasca-inc-for-16-november-93CH-5707773
The article reports on the filing of Form 144 by Erasca Inc. on November 16. Form 144 is a notice of the intent to sell restricted securities. The brief article, published by Investing.com, indicates the date of the filing for the company, Erasca Inc. (ERAS).

Form 144 Erasca Inc. For: 16 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-erasca-inc-for-16-november-93CH-4961806
This article from Investing.com announces the filing of Form 144 for Erasca Inc. on November 16, 2026. Form 144 is a notice of the intent to sell restricted securities, indicating potential insider activity. The article itself is brief, primarily serving as an announcement for the regulatory filing.

Erasca (ERAS): Erasca Foundation proposes a share sale valued at about $129K.

https://www.stocktitan.net/sec-filings/ERAS/144-erasca-inc-sec-filing-6d0c17beabd5.html
The Erasca Foundation has filed a Form 144 notice proposing the sale of 8,333 common shares of Erasca, Inc. (ERAS), with an approximate market value of $129,255.86 and an approximate sale date of November 16, 2026. The foundation originally acquired over a million shares by donation from Erasca, Inc. in July 2021. This filing also details previous sales by the foundation, each involving 8,333 shares, in August, September, and October 2026.
Advertisement

T. Rowe Price reports 17.2M Erasca (ERAS) shares but expressly denies beneficial ownership.

https://www.stocktitan.net/sec-filings/ERAS/schedule-13g-a-erasca-inc-amended-passive-investment-disclosure-130efe8eaf51.html
T. Rowe Price Investment Management, Inc. filed an amended ownership report for Erasca, Inc. (ERAS), indicating 17,212,014 common shares, or 4.9% of the class, as of September 30, 2026. Despite reporting these shares, the firm explicitly denied beneficial ownership. This filing provides details on sole voting and dispositive power held by T. Rowe Price.

Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise

https://www.manilatimes.net/2026/11/16/tmt-newswire/globenewswire/erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-across-its-ras-targeting-franchise/2470944
Erasca, Inc. will host a virtual investor event on November 20, 2026, to discuss updated Phase 1 data for ERAS-0015, a pan-RAS molecular glue, and other updates following its presentations at the EORTC-NCI-AACR Symposium. The event will highlight the clinical momentum of its RAS-targeting franchise, including data for ERAS-0015 in RAS-mutant solid tumors and preclinical data for ERAS-4001, a pan-KRAS inhibitor. Erasca aims to develop therapies for RAS/MAPK pathway-driven cancers.

Erasca Announces Virtual Investor Event to Discuss Updated Phase 1 Data for ERAS-0015 and Other Updates

https://www.quiverquant.com/news/Erasca+Announces+Virtual+Investor+Event+to+Discuss+Updated+Phase+1+Data+for+ERAS-0015+and+Other+Updates
Erasca, Inc. will host a virtual investor event on November 20, 2026, to discuss updated Phase 1 data for ERAS-0015, a pan-RAS molecular glue for RAS-mutant solid tumors, and other company updates. This event follows presentations at the 38th EORTC-NCI-AACR Symposium. Early data for ERAS-0015 shows favorable safety, tolerability, and confirmed partial responses, while ERAS-4001, a pan-KRAS inhibitor, has demonstrated promising preclinical activity.

Erasca will discuss updated human-trial data on an experimental cancer treatment Nov. 20.

https://www.stocktitan.net/news/ERAS/erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-lw6znzm7pxrc.html
Erasca (NASDAQ: ERAS) is set to host a virtual investor event on November 20, 2026, at 8:00 a.m. Eastern Time. The event will focus on updated Phase 1 data for ERAS-0015, an experimental pan-RAS molecular glue for RAS-mutant solid tumors, and other company updates. This discussion follows presentations at the EORTC-NCI-AACR Symposium, where clinical and nonclinical data for ERAS-0015 and ERAS-4001 combination were presented.

Erasca Q3FY26 Results: Net loss widens 68% YoY to $51.3 million

https://scanx.trade/stock-market-news/companies/erasca-q3fy26-results-net-loss-widens-68-yoy-51-3-million/56063448
Erasca Inc. reported a Q3FY26 loss per share of $(0.15), missing estimates, with its net loss widening by 68% year-over-year to $51.3 million. This increase was primarily driven by a more than doubling of research and development expenses to $47.2 million as the company advanced its clinical pipeline. Despite the widening loss, Erasca's cash reserves significantly strengthened to $947.8 million following a public offering in July 2026, providing a substantial buffer for accelerated R&D.
Advertisement

Erasca, Inc. (ERAS) Misses Q3 EPS by 2c

https://www.streetinsider.com/Earnings/Erasca%2C+Inc.+%28ERAS%29+Misses+Q3+EPS+by+2c/27337904.html
Erasca, Inc. (NASDAQ: ERAS) reported its Q3 EPS, missing analyst estimates by $0.02. The company's Q3 EPS was ($0.15) compared to the analyst estimate of ($0.13). This report provides key financial performance data for serious traders.

Form 8K Erasca Inc For: 12 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-erasca-inc-for-12-november-93CH-4954206
This article from Investing.com announces the filing of a Form 8K by Erasca Inc. on November 12. It provides no further details about the content of the Form 8K, simply stating its publication. The article primarily serves as a placeholder for this financial filing announcement, noting the company's stock symbol ERAS.

Erasca COO departure sparks securities fraud investigation after stock drops nearly 10%

https://pluang.com/en/news-feed/peringatan-investor-pomerantz-selidiki-tuntutan-penipuan-sekuritas-erasca
Erasca, Inc. announced the termination of its Chief Operating Officer, Nicholas Chetwyn, leading to a nearly 10% drop in its stock price. This has prompted Pomerantz LLP to launch an investigation into potential securities fraud or unlawful business practices. Investors affected by the stock's decline are encouraged to contact the law firm regarding possible class action participation.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS

https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-erasca-inc---eras-302937414.html
Pomerantz LLP is investigating potential securities fraud claims against Erasca, Inc. (NASDAQ: ERAS) following a 9.95% drop in its stock price on October 16, 2026. This decline occurred after Erasca announced the termination of its Chief Operating Officer, Nicholas Chetwyn, citing a realignment of leadership responsibilities. The firm encourages affected investors to contact them for more information regarding joining a potential class action lawsuit.

Erasca (ERAS) Stock Price, Chart & Analysis

https://www.debelegger.nl/en/stock/ERAS.US
This article provides a detailed analysis of Erasca (ERAS) stock, covering its current price, market capitalization, financial performance, and analyst ratings. It highlights that Erasca pays no dividend, has grown revenue by 0% in the last quarter, and maintains a net cash position. The analysis also includes key financial ratios and a comparison with sector peers.
Advertisement

Attention Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Planet Fitness, Inc. (NYSE: PLNT); The Simply Good Foods Company (NASDAQ: SMPL); and Sprout Social, Inc. (NASDAQ: SPT): Grabar Law Office is Investigating Claims on Your Behalf

https://www.globenewswire.com/news-release/2026/11/09/3398386/0/en/attention-long-term-shareholders-of-erasca-inc-nasdaq-eras-planet-fitness-inc-nyse-plnt-the-simply-good-foods-company-nasdaq-smpl-and-sprout-social-inc-nasdaq-spt-grabar-law-office.html
Grabar Law Office is investigating potential breaches of fiduciary duty by officers and directors of Erasca, Inc., Planet Fitness, Inc., The Simply Good Foods Company, and Sprout Social, Inc. The investigations focus on alleged misleading statements and omissions, and shareholders who held shares prior to specific dates are encouraged to contact the firm for potential corporate governance reforms and damages.

Erasca COO departure sparks securities fraud investigation, stock drops nearly 10%

https://pluang.com/en/news-feed/peringatan-investor-pomerantz-selidiki-tuntutan-terhadap-erasca
Erasca, Inc. announced the termination of its Chief Operating Officer, Nicholas Chetwyn, leading to a nearly 10% drop in its stock price. This has prompted Pomerantz LLP to launch an investigation into potential securities fraud or other unlawful practices by the company and its officers. The investigation highlights concerns about corporate governance and could significantly impact Erasca's future operations and investor confidence.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS

https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-erasca-inc---eras-302931425.html
Pomerantz LLP is investigating potential securities fraud claims against Erasca, Inc. following a significant drop in its stock price. The investigation stems from the termination of the company's Chief Operating Officer, Dr. Nicholas Chetwyn, which Erasca attributed to a leadership realignment. The announcement on October 16, 2026, led to a 9.95% decline in Erasca's stock.

Pomerantz LLP investigates Erasca for possible securities fraud after COO termination and stock drop.

https://pluang.com/en/news-feed/pomerantz-selidiki-klaim-investor-erasca-penipuan-sekuritas
Pomerantz LLP has initiated an investigation into Erasca, Inc. for potential securities fraud following the termination of its COO, Nicholas Chetwyn. This leadership change led to a significant drop in Erasca's stock price, prompting concerns about possible unlawful practices by the company and its executives. The firm is encouraging affected investors to contact them regarding potential participation in a class action lawsuit.

│Important Notice to Long-Term Shareholders of Erasca, Inc.

https://www.globenewswire.com/news-release/2026/11/04/3395637/0/en/important-notice-to-long-term-shareholders-of-erasca-inc-nasdaq-eras-o-i-glass-inc-nyse-oi-planet-fitness-inc-nyse-plnt-and-sprout-social-inc-nasdaq-spt-grabar-law-office-is-invest.html
│Grabar Law Office is investigating potential breaches of fiduciary duty by officers and directors of Erasca, Inc., O-I Glass, Inc., Planet Fitness, Inc., and Sprout Social, Inc. The investigations concern alleged misleading statements and omissions related to product development, financial performance, and marketing strategies, which reportedly led to substantial stock price declines. Shareholders who held shares prior to specific dates are encouraged to contact the firm for potential corporate governance reforms and damages.
Advertisement

Two experimental cancer drugs are being tested together in patients with certain pancreatic and lung cancers

https://www.stocktitan.net/news/TNGX/tango-and-erasca-initiate-phase-1-2-study-of-oral-prmt5-inhibitor-ffzzpl3gou4p.html
Tango Therapeutics (TNGX) and Erasca (ERAS) have initiated a Phase 1/2 clinical trial to evaluate the combination of their experimental drugs, vopimetostat and ERAS-0015, for treating specific pancreatic and lung cancers. The study aims to determine the maximum tolerated dose, as well as assess the antitumor activity, safety, and tolerability of the combination in patients with MTAP-deleted pancreatic ductal adenocarcinoma or MTAP-deleted/RAS-mutant non-small cell lung cancer. Both companies express optimism about the synergistic potential of co-targeting PRMT5 and RAS pathways for deeper and more durable responses in these difficult-to-treat cancers.

Erasca to Present at Upcoming Conferences in November

https://www.manilatimes.net/2026/11/03/tmt-newswire/globenewswire/erasca-to-present-at-upcoming-conferences-in-november/2460624/amp
Erasca, Inc. (Nasdaq: ERAS), a precision oncology company, announced that its management will participate in three investor conferences in November 2026. These include the Guggenheim 3rd Annual Healthcare Innovation Conference, the Stifel 2026 Healthcare Conference, and the Jefferies Global Healthcare Conference, where management will engage in fireside chats and one-on-one investor meetings. Live audio webcasts and archived replays of these events will be available on the company's website.

Three Erasca conference sessions will stream live, with 30-day replays.

https://www.stocktitan.net/news/ERAS/erasca-to-present-at-upcoming-conferences-in-59sfg1up3tjs.html
Erasca (ERAS) management will participate in three investor conferences in November 2026, featuring fireside chats and one-on-one investor meetings. These events will be held in Boston, New York, and London, with live audio webcasts and 30-day archived replays available on Erasca.com/events. The company, a clinical-stage precision oncology firm, focuses on therapies for RAS/MAPK pathway-driven cancers.

Erasca (ERAS) Analyst Ratings, Stock Forecast and Price Target

https://www.moomoo.com/stock/ERAS-US/forecast?chain_id=Name1K9-3FXPhg.1kmav7g&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A57,%22f%22%3A%22www.moomoo.com%2Fstock%2FRGC-US%22%7D
This article provides an overview of analyst ratings and price targets for Erasca (ERAS), a clinical-stage oncology company. It includes details on recent analyst actions, consensus recommendations, and the methodology behind the stock forecast. The report aims to offer insights into ERAS's potential stock performance based on expert opinions.

Erasca, Inc. (ERAS) Seasonal returns chart

https://uk.finance.yahoo.com/quote/ERAS/seasonality/
This article provides a seasonal returns chart for Erasca, Inc. (ERAS), displaying the average monthly price return from 2021 to 2026. As of the stated time, Erasca, Inc. (ERAS) stock was trading at 14.74, up 4.91%. The content focuses on the historical seasonality of the stock's performance.
Advertisement

Erasca, Inc. (ERAS) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/ERAS/seasonality/
This article from Yahoo Finance provides a seasonal returns chart for Erasca, Inc. (ERAS). It displays the average monthly price return for ERAS between 2021 and 2026, along with current stock information and market data.

Erasca COO departure sparks stock drop and secu...

https://pluang.com/en/news-feed/peringatan-investor-pomerantz-lawan-selidiki-tuntutan-penipuan-sekuritas-erasca
Erasca, Inc. announced the termination of its Chief Operating Officer, Dr. Nicholas Chetwyn, effective November 2, 2026, leading to a nearly 10% drop in stock price. Following this, Pomerantz LLP launched an investigation into potential securities fraud by Erasca and its executives. The company's stock, ERAS, currently trades at USD 15.18, up 0.40% for the day, with a market cap of $5.30 billion.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS

https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-erasca-inc---eras-302922994.html
Pomerantz LLP is investigating potential securities fraud claims against Erasca, Inc. (NASDAQ: ERAS) following the termination of its Chief Operating Officer, Nicholas Chetwyn. The investigation was prompted by a 9.95% drop in Erasca's stock price after the company announced Chetwyn's departure, citing a realignment of leadership responsibilities for its RAS-targeting programs. Investors who suffered losses are encouraged to contact the law firm to learn about joining the class action.

Law firm investigates fiduciary breaches at Erasca, Planet Fitness, PROCEPT, and Simply Good Foods.

https://pluang.com/en/news-feed/investigasi-grabarlaw-erasca-planet-fitness-procept-simply-good-foods
Grabar Law Office is investigating potential breaches of fiduciary duties by officers and directors at Erasca, Planet Fitness, PROCEPT BioRobotics, and The Simply Good Foods Company. The investigations center on alleged misleading statements and omissions concerning product development, marketing, sales, and acquisition integration, which may have harmed shareholders. Affected shareholders who held shares before specific dates are encouraged to contact the firm to seek reforms, damages, and court-approved awards without personal cost.

Law firm investigates Erasca over COO terminati...

https://pluang.com/en/news-feed/peringatan-investor-pomerantz-lawan-selidiki-erasca-inc
Pomerantz LLP is investigating Erasca, Inc. after the termination of COO Nicholas Chetwyn led to a nearly 10% stock price drop. The investigation will determine if Erasca engaged in securities fraud or other unlawful practices, which could impact investor confidence and future operations. Erasca's stock currently trades at USD 15.14, with Pluang showing 100% sell order activity due to cautious investor sentiment.
Advertisement

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Erasca (ERAS) and Incyte (INCY)

https://www.theglobeandmail.com/investing/markets/stocks/MRK/pressreleases/8471201/analysts-offer-insights-on-healthcare-companies-merck-company-mrk-erasca-eras-and-incyte-incy/
This article provides an overview of recent analyst ratings for three healthcare companies: Merck & Company (MRK), Erasca (ERAS), and Incyte (INCY). Analysts from Bernstein, Bank of America Securities, and Cantor Fitzgerald have issued "Hold" or "Buy" ratings with specific price targets and discussed their average returns and success rates. The consensus for all three companies is a "Moderate Buy" with varying upside potentials.

ERAS Investors with $100,000 in Losses Have Opportunity to Join Erasca, Inc. Fraud Investigation with SBS Law

https://www.businesswire.com/news/home/20261023212754/en/ERAS-Investors-with-%24100000-in-Losses-Have-Opportunity-to-Join-Erasca-Inc.-Fraud-Investigation-with-SBS-Law
Schall, Brown & Schwartz LLP (SBS) has initiated an investigation into Erasca, Inc. (NASDAQ: ERAS) following a 9.95% drop in stock price on October 16, 2026. This downturn occurred after Erasca announced the termination of its Chief Operating Officer, Nicholas (Nik) Chetwyn, Ph.D., effective November 2, 2026, citing a realignment of leadership responsibilities. SBS is inviting investors who have suffered losses of $100,000 or more to join their fraud investigation, alleging potential violations of securities laws by the company.

Erasca, Inc. Estimates – NASDAQ:ERAS

https://www.tradingview.com/symbols/NASDAQ-ERAS/financials-estimates/
This article provides an overview of Erasca, Inc. (NASDAQ: ERAS) financial estimates and actuals through TradingView. It allows users to explore reported financial data and analyst estimates across various financial statements and valuation metrics. The platform enables comparison of actual results with average, high, and low estimates, and visualization of trends over time.

ERAS Investors with $100,000 in Losses Have Opportunity to Join Erasca, Inc. Fraud Investigation with SBS Law

https://www.financialcontent.com/article/bizwire-2026-10-23-eras-investors-with-100000-in-losses-have-opportunity-to-join-erasca-inc-fraud-investigation-with-sbs-law
Schall, Brown & Schwartz LLP (SBS) has launched an investigation into Erasca, Inc. (NASDAQ: ERAS) following a 9.95% drop in stock value after the company announced the termination of its Chief Operating Officer, Nicholas Chetwyn. The investigation seeks to determine if Erasca made false or misleading statements to investors. Shareholders who experienced losses are encouraged to contact SBS Law to discuss their rights.

Important Notice to Long-Term Shareholders of Coastal Financial Corporation (NASDAQ: CCB); D-Wave Quantum Inc. (NASDAQ: QBTS); Erasca, Inc. (NASDAQ: ERAS) and Planet Fitness, Inc. (NYSE: PLNT): Grabar Law Office is Investigating Claims on Your Behalf

https://www.mycarrollcountynews.com/online_features/press_releases/article_09d1c4ca-1143-5a46-9aef-87a3a9cb8681.html
Grabar Law Office is investigating potential breaches of fiduciary duties and other alleged misconduct by officers and directors of Coastal Financial Corporation (NASDAQ: CCB), D-Wave Quantum Inc. (NASDAQ: QBTS), Erasca, Inc. (NASDAQ: ERAS), and Planet Fitness, Inc. (NYSE: PLNT). These investigations stem from alleged misleading statements, undisclosed risks, and poor financial performance that impacted shareholder value. Long-term shareholders of these companies are encouraged to contact Grabar Law Office for more information on potential corporate reforms and seeking damages.
Advertisement

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS

https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-erasca-inc---eras-302916531.html
Pomerantz LLP is investigating potential securities fraud claims against Erasca, Inc. following a significant drop in its stock price. The investigation was initiated after Erasca announced the termination of its Chief Operating Officer, Nicholas Chetwyn, citing a realignment of leadership responsibilities. This news led to a nearly 10% fall in Erasca's stock on October 16, 2026.

Law firm probes Erasca after COO exit causes stock to drop nearly 10%. ERAS

https://pluang.com/en/news-feed/peringatan-investor-pomerantz-lawan-erasca-inc
Pomerantz LLP is investigating Erasca, Inc. for potential securities fraud following the announced departure of COO Nicholas Chetwyn, which caused a nearly 10% drop in Erasca's stock. The company cited a leadership realignment, but the investigation will examine if unlawful practices affected shareholders. Despite the news, Erasca's stock saw a 7.27% gain on Pluang, with high investor interest.

Erasca (ERAS) Stock Looks Above Fair Value After Its 5x Run

https://finance.yahoo.com/markets/stocks/articles/erasca-eras-stock-looks-above-060857688.html
Erasca's stock (ERAS) has seen a significant 5x increase over the past three years, raising questions about whether its current valuation is supported by its balance sheet and book value. Despite recent legal scrutiny concerning its ERAS-0015 program disclosures, the stock trades at a high P/B ratio of 12.9x, far above the biotech sector average, suggesting it may be overvalued relative to its net assets. The article emphasizes that while some market narratives consider Erasca undervalued based on early clinical data, investors should carefully assess the durability of its capital base and potential impacts of future funding rounds.

Form 144 Erasca For: 15 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-144-erasca-for-15-october-93CH-2739013
This article from Investing.com reports on a Form 144 filing for Erasca dated October 15. The brief piece includes market data for various indices, commodities, bonds, and shares, indicating minor fluctuations. It also highlights trending stocks and top-performing AI-powered stock picks.

An 8,333-share Erasca (ERAS) sale is proposed by Erasca Foundation, with shares valued at $122K.

https://www.stocktitan.net/sec-filings/ERAS/144-erasca-inc-sec-filing-942f245a7eb1.html
The Erasca Foundation has proposed selling 8,333 common shares of Erasca, Inc. (ERAS), valued at approximately $122,353. The sale is scheduled for October 15, 2026, through Merrill Lynch. This proposed sale follows three previous sales of 8,333 shares each in July, August, and September 2026.
Advertisement

Form 144 Erasca For: 15 October By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-erasca-for-15-october-93CH-4883611
This article from Investing.com is a straightforward notification regarding a Form 144 filing for Erasca, dated October 15. The content is brief, primarily serving as an alert for investors interested in ERAS, and includes a link to related financial data and market performance for the company.

Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your Behalf

https://www.mycarrollcountynews.com/online_features/press_releases/article_dc8eaa5d-d129-5d72-addd-ec60108c3aa5.html
Grabar Law Office is investigating potential claims on behalf of long-term shareholders of Aardvark Therapeutics, Inc. (AARD), Coastal Financial Corporation (CCB), Erasca, Inc. (ERAS), and Power Solutions International, Inc. (PSIX). The investigations concern alleged breaches of fiduciary duties and securities fraud, including misleading statements regarding product safety, financial performance, and business prospects. Shareholders who held shares before specific dates are encouraged to contact the law office for potential corporate reforms and financial recovery.

Important Notice to Long-Term Shareholders of American Express Company (NYSE: AXP); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS) and Planet Fitness, Inc. (NYSE: PLNT): Grabar Law Office is Investigating Claims on Your Behalf

https://www.lincolnjournal.com/online_features/press_releases/important-notice-to-long-term-shareholders-of-american-express-company-nyse-axp-coastal-financial-corporation/article_ed773f5d-5b5e-5db7-af90-dd9968103589.html
Grabar Law Office is investigating claims on behalf of long-term shareholders of American Express Company (AXP), Coastal Financial Corporation (CCB), Erasca, Inc. (ERAS), and Planet Fitness, Inc. (PLNT). The investigations concern potential breaches of fiduciary duties and misleading statements made by certain officers and directors of these companies. Shareholders who held shares prior to specific dates are encouraged to contact the law office for more information regarding potential corporate governance reforms and recovery of losses.

ERAS: Erasca Inc Latest Stock Price, Analysis, News and Trading Ideas

https://stocktwits.com/symbol/ERAS
Erasca, Inc. (ERAS) is a clinical-stage oncology company focused on RAS/MAPK pathway-driven cancers. The stock recently saw a significant jump but is now subject to a legal investigation, which introduces risk. Despite some upside interest observed in call options, the overall sentiment is cautious due to potential volatility.

ERAS Stock Technical Analysis

https://pluang.com/en/asset/usstock/ERAS/11347/technicals
This article provides a technical analysis of Erasca Inc. Common Stock (ERAS), detailing its current stock price, market capitalization, trading volume, and 52-week high and low. It highlights that the stock has traded between $2.2 and $22.47 over the past year. The article encourages users to track ERAS stock on Pluang, an OJK-regulated platform, offering real-time market data and fractional share trading.
Advertisement

Grabar Law investigates shareholder claims against Aardvark, Coastal Financial, Erasca, and New Era Energy for alleged misconduct.

https://pluang.com/en/news-feed/investigasi-hukum-untuk-pemegang-saham-aardvark-terapeutics-dan-coastal
Grabar Law Office is investigating shareholder claims against Aardvark Therapeutics, Coastal Financial Corporation, Erasca, Inc., and New Era Energy & Digital for alleged securities violations and breaches of fiduciary duties. These investigations stem from misleading statements related to drug safety, credit quality, clinical trial data, and project progress, which led to significant stock price declines. Shareholders who bought shares around IPO dates and still hold them may be eligible for corporate reforms and financial recovery.

Erasca stock heads toward November cancer data presentations

https://www.ad-hoc-news.de/boerse/news/nebenwerte/erasca-stock-heads-toward-november-cancer-data-presentations/70246620
Erasca stock is trading at USD 14.30, 41.1% below its 52-week high, as the company prepares for upcoming clinical data presentations at the ENA Symposium in November 2026. These presentations will include updated monotherapy data for ERAS-0015 and nonclinical combination data for ERAS-0015 and ERAS-4001. Analyst consensus indicates a "Moderate Buy" with an average 12-month price target of USD 22.09, despite a recent Q2 loss that missed estimates.

Erasca announces ERAS-0015 data: what it means for Erasca stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/erasca-announces-eras-0015-data-what-it-means-for-erasca-stock/70238424
Erasca reported a 57.00 percent eight-week response rate for ERAS-0015 in pancreatic cancer, with expanded clinical data to be presented in November 2026. This data, while preliminary, offers a clear milestone for the company, whose stock performance relies heavily on clinical progress rather than current product revenue. Analysts largely rate Erasca as a "Buy," reflecting the potential of its clinical-stage oncology programs.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Erasca, Inc. (ERAS) And Encourages Investors to Reach Out

https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-initiates-an-investigation-in-1232220
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Erasca, Inc. (NASDAQ:ERAS). The firm is encouraging investors who purchased Erasca securities before January 14, 2025, and still hold them, to come forward and assist with the investigation. The firm operates on a contingency fee basis, only seeking reimbursement if successful.

Erasca secures $1B funding, advancing RAS-targeted cancer trials with promising drug ERAS-0015.

https://pluang.com/en/news-feed/erasca-persetujuan-revolusi-mengurangi-risiko-pengikut-cepat
Erasca has secured approximately $1 billion in funding, establishing itself as a significant player in RAS-targeted oncology with three potential registration trials on the horizon. The company's drug ERAS-0015 shows promise in terms of tolerability and dose intensity, differentiating it from competitors like Daraxonrasib. Despite ongoing patent litigation and safety risks, Erasca's valuation appears to already account for these concerns, potentially overlooking its recent positive clinical advancements.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement